5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole | 151273-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole
• 英文别名: 4-(5-amino-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid ter-butyl ester；tert-butyl 4-(5-amino-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 4-(5-amino-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 151273-39-1
• 化学式: C₁₈H₂₃N₃O₂
• 分子量: 313.4
• InChiKey: SVFQWDXQGMOVNW-UHFFFAOYSA-N

物化性质

• 沸点：
  522.5±50.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-溴-2,4-二氯嘧啶 、 5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole 在 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 19.0h， 以23%的产率得到4-{5-[5-bromo-4-(4-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1H-indol-3-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  [FR] COMPOSES POUR TRAITER LE DEVELOPPEMENT ANORMAL DE CELLULES

  摘要：

  公开号：

  WO2004056786A3
• 作为产物：
  描述：

  tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate 在 铁粉 氯化铵 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 3.0h， 以94%的产率得到5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  [FR] COMPOSES POUR TRAITER LE DEVELOPPEMENT ANORMAL DE CELLULES

  摘要：

  公开号：

  WO2004056786A3
• 作为试剂：
  描述：

  tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate 、 氯化铵 在 铁粉 1,4-二氧六环 、 乙醇 、 水 、 氩 、 甲醇 、 silica gel 、 5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole 作用下， 反应 3.0h， 以to afford the desired compound tert-butyl 4-(5-amino-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate的产率得到5-Amino-3-(N-t-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)-1H-indole
  参考文献：
  名称：

  INHIBITORS OF FOCAL ADHESION KINASE

  摘要：

  本发明提供了针对聚焦粘附激酶（一种酶，参与细胞细胞骨架与细胞外基质的结合）的抑制剂，该酶被认为参与细胞迁移、细胞增殖和细胞存活等过程。这些抑制剂是5-取代的2,4-二氨基吡啶的衍生物，其中取代基如此定义。本发明还提供了使用这些抑制剂治疗癌症的方法，以及通过使用偶联反应制备这些抑制剂的方法。

  公开号：

  US20130281443A1

文献信息

• Compound for the treatment of abnormal cell growth
  申请人：Pfizer Inc

  公开号：US20040220177A1

  公开（公告）日：2004-11-04

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, A and B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及公式11的化合物，以及其药物可接受的盐、前药和溶剂化物，其中R1、R2、R3、R4、R5、n、A和B的定义如本文所述。本发明还涉及通过给予公式1的化合物治疗哺乳动物异常细胞生长的方法，并涉及用于治疗此类疾病的制药组合物，其中包含公式1的化合物。本发明还涉及制备公式1的化合物的方法。
• Indole derivatives
  申请人：Pfizer Inc

  公开号：US05639752A1

  公开（公告）日：1997-06-17

  Compounds of the formula ##STR1## wherein Z is ##STR2## R.sub.1 is ##STR3## X is O, NH, or S; A, B, D, E, and F are each independently C, N, O, or S; wherein the remaining variables are defined in the specification, and the pharmaceutically acceptable salts thereof. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  化合物的公式为##STR1##其中Z为##STR2##R.sub.1为##STR3##X为O、NH或S；A、B、D、E和F各自独立地为C、N、O或S；其余变量在说明书中定义，并且其药学上可接受的盐。这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT1）激动剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、簇头痛、偏头痛、疼痛、慢性阵发性半枕状神经痛和与血管紊乱相关的头痛以及由于5-羟色胺能神经递质缺乏引起的其他疾病。这些化合物也可用作中枢作用的降压药和扩血管药。
• 5-arylindole derivatives
  申请人：Pfizer Inc.

  公开号：US05886008A1

  公开（公告）日：1999-03-23

  Compounds of formula (I), wherein R.sub.1 is (a), (b), (c) or (d); n is 0, 1 or 2; A, B, C and D are each independently nitrogen or carbon; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, nitro, --(CH.sub.2).sub.m NR.sub.14 R.sub.15, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.14 R.sub.15, --(CH.sub.2).sub.m NR.sub.14 SO.sub.2 R.sub.15 --(CH.sub.2).sub.m NR.sub.14 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.14 COR.sub.9, --(CH.sub.2).sub.m NR.sub.14 CONHR.sub.9, --CONR.sub.14 R.sub.15, or --CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, or R.sub.4 and R.sub.5 may be taken together to form a five- to seven-membered alkyl ring, a six-membered aryl ring, a five- to seven-membered heteroalkyl ring having 1 heteroatom of N, O, or S, or a five- to six-membered heteroaryl ring having H 1 or 2 heteroatoms of N, O, or S and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and benzodiazepine agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vosodilators. ##STR1##

  式(I)的化合物，其中R.sub.1是(a)，(b)，(c)或(d)；n为0，1或2；A，B，C和D各自独立地为氮或碳；R.sub.2，R.sub.3，R.sub.4和R.sub.5各自独立地为氢，C.sub.1至C.sub.6烷基，芳基，C.sub.1至C.sub.3烷基芳基，卤素（例如氟，氯，溴或碘），氰基，硝基，--(CH.sub.2).sub.m NR.sub.14 R.sub.15，--(CH.sub.2).sub.m OR.sub.9，--SR.sub.9，--SO.sub.2 NR.sub.14 R.sub.15，--(CH.sub.2).sub.m NR.sub.14 SO.sub.2 R.sub.15，--(CH.sub.2).sub.m NR.sub.14 CO.sub.2 R.sub.9，--(CH.sub.2).sub.m NR.sub.14 COR.sub.9，--(CH.sub.2).sub.m NR.sub.14 CONHR.sub.9，--CONR.sub.14 R.sub.15，或--CO.sub.2 R.sub.9；R.sub.2和R.sub.3，R.sub.3和R.sub.4，或R.sub.4和R.sub.5可以共同形成五到七元的烷基环，六元的芳基环，具有1个N、O或S杂原子的五到七元的杂烷基环或具有1或2个N、O或S杂原子的五到六元的杂芳基环及其药学上可接受的盐。这些化合物对治疗偏头痛和其他疾病有用。这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT.sub.1）激动剂和苯二氮平激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、集群头痛、偏头痛、疼痛和慢性阵发性半侧头痛以及与缺乏5-羟色胺能神经递质有关的其他疾病。这些化合物还可用作中枢作用降压剂和扩血管剂。
• Inhibitors of focal adhesion kinase
  申请人：Liang Congxin

  公开号：US08501763B2

  公开（公告）日：2013-08-06

  The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

  本发明提供了针对聚焦粘附激酶（一种参与细胞细胞骨架与细胞外基质附着的酶）的抑制剂，该酶被认为参与了细胞迁移、细胞增殖和细胞存活等过程。这些抑制剂是5-取代-2,4-二氨基吡啶的衍生物，其中取代基如本文所定义。本发明还提供了一种使用这些抑制剂治疗癌症的方法，以及通过使用偶联反应制备这些抑制剂的方法。
• 5-arylindolederivatives and their use as serotonin(5-ht1)agonists
  申请人：PFIZER INC.

  公开号：EP1094064A1

  公开（公告）日：2001-04-25

  A compound of the formula wherein R1 is n is 0, 1, or 2; A, B, C, and D are each independently nitrogen or carbon; R2, R3, R4, and R5 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkyl-aryl, halogen, cyano, nitro, -(CH2)mNR14R15, -(CH2)mOR9, -SR9, -SO2NR14R15, -(CH2)mNR14SO2R15, -(CH2)mNR14CO2R9, -(CH2)mNR14COR9, -(CH2)mNR14CONHR9, -CONR14R15, or -CO2R9; R2 and R3, R3 and R4, or R4 and R5 may be taken together to form a five- to seven-membered alkyl ring, a six-membered aryl ring, a five- to seven-membered heteroalkyl ring having 1 heteroatom of N, O, or S, or a five- to six-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R6 is hydrogen, -OR10, or -NHCOR10; R7, R8, R14, and R15 are each independently hydrogen, C1 to C6 alkyl, -(CH2)xOR11, C1 to C3 alkyl-aryl, aryl; R7 and R8 or R14 and R15 may be taken together to form a three- to six-membered ring; R9 is hydrogen, C1 to C6 alkyl, C1 to C3 alkyl-aryl, or aryl; R10 is hydrogen, C1 to C6 alkyl, or C1 to C3 alkyl-aryl; R11 is hydrogen, C1 to C6 alkyl, or C1 to C3 alkyl-aryl; m is 0, 1, 2, or 3; x is 2 or 3; a broken line represents an optional double bond; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently phenyl or substituted phenyl, wherein said substituted phenyl may be substituted with one to three of C1 to C4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, or C1 to C4 alkoxy; or a pharmaceutically acceptable satt thereof.

  式中的化合物 其中 R1 是 n为0、1或2；A、B、C和D各自独立地为氮或碳；-(CH2)mOR9、-SR9、-SO2NR14R15、-( )mNR14SO2R15、-( )mNR14CO2R9、-( )mNR14COR9、-( )mNR14CONHR9、-CONR14R15 或 -CO2R9；R2 和 R3、R3 和 R4 或 R4 和 R5 可组合成五至七元烷基环、六元芳基环、具有 1 个 N、O 或 S 杂原子的五至七元杂烷基环或具有 1 或 2 个 N、O 或 S 杂原子的五至六元杂芳基环；R6是氢、-OR10或-NHCOR10； R7、R8、R14和R15各自独立地是氢、C1至C6烷基、-( )xOR11、C1至C3烷基芳基、芳基；R7 和 R8 或 R14 和 R15 可结合在一起形成三至六元环；R9 是氢、C1 至 C6 烷基、C1 至 C3 烷基芳基或芳基；R10 是氢、C1 至 C6 烷基或 C1 至 C3 烷基芳基；R11 是氢、C1 至 C6 烷基或 C1 至 C3 烷基芳基；m 是 0、1、2 或 3；x 是 2 或 3；断线代表任选双键；上述芳基和上述烷基芳基的芳基独立地为苯基或取代苯基，其中所述取代苯基可被 C1 至 C4 烷基、卤素、羟基、氰基、羧酰胺基、硝基或 C1 至 C4 烷氧基中的一至三个取代；或其药学上可接受的酯。